Institution
Rotterdam University of Applied Sciences
Education•Rotterdam, Netherlands•
About: Rotterdam University of Applied Sciences is a education organization based out in Rotterdam, Netherlands. It is known for research contribution in the topics: Population & Health care. The organization has 937 authors who have published 1113 publications receiving 27447 citations.
Topics: Population, Health care, Psychological intervention, Myocardial infarction, Coronary artery disease
Papers published on a yearly basis
Papers
More filters
••
TL;DR: Preliminary data suggest that MSCT allows non-invasive imaging of coronary-artery stenoses and has potential to develop into a reliable clinical technique.
750 citations
••
TL;DR: The psychometric properties of the Tilburg Frailty Indicator are good, when performed in 2 samples of community-dwelling older people, providing strong evidence for an integral definition of frailty consisting of physical, psychological, and social domains.
672 citations
••
Harvard University1, Rotterdam University of Applied Sciences2, NewYork–Presbyterian Hospital3, University of Pennsylvania4, Emory University5, Heidelberg University6, University of Salamanca7, University of Barcelona8, University of Turin9, St Bartholomew's Hospital10, Mayo Clinic11, University of Michigan12, Millennium Pharmaceuticals13, Genentech14
TL;DR: The activity of bortezomib is confirmed and support extended treatment in relapsed multiple myeloma patients tolerating therapy and among responding patients, 56% improved response with longer therapy beyond initial response, leading to continued improvement in overall quality of response.
497 citations
••
TL;DR: The ILP with TNF + melphalan can be performed safely in many centers and is an effective induction treatment with a high response rate that can achieve limb salvage in patients with locally advanced extremity soft tissue sarcoma.
Abstract: OBJECTIVE: The objective of the study was to achieve limb salvage in patients with locally advanced soft tissue sarcomas that can only be treated by amputation or functionally mutilating surgery by performing an isolated limb perfusion (ILP) with tumor necrosis factor (TNF) + melphalan (M) as induction biochemotherapy to obtain local control and make limb-sparing surgery possible. SUMMARY BACKGROUND DATA: To increase the number of limb-sparing resections in the treatment of locally advanced extremity soft tissue sarcoma, preoperative radiation therapy or chemotherapy or a combination of the two often are applied. The ILP with cytostatic agents alone is another option but rarely is used because of rather poor results. The efficacy of the application of TNF in ILP markedly has changed this situation. METHODS: In 8 cancer centers, 186 patients were treated over a period of almost 4.5 years. There were 107 (57%) primary and 79 (43%) recurrent sarcomas, mostly high grade (110 grade III; 51 grade II; and 25 very large, recurrent, or multiple grade I sarcomas). The composition of this series of patients is unusual: 42 patients (23%) had multifocal primary or multiple recurrent tumors; median tumor size was very large (16 cm); 25 patients (13%) had known systemic metastases at the time of the ILP. Patients underwent a 90-minute ILP at 39 to 40 C with TNF + melphalan. The first 55 patients also received interferon-tau. A delayed marginal resection of the tumor remnant was done 2 to 4 months after ILP. RESULTS: A major tumor response was seen in 82% of the patients rendering these large sarcomas resectable in most cases. Clinical response rates were: 33 complete response (CR) (18%), 106 partial response (PR) (57%), 42 no change (NC) (22%), and 5 progressive disease (PD) (3%). Final outcome was defined by clinical and pathologic response: 54 CR (29%), 99 PR (53%), 29 NC (16%), and 4 PD (2%). At a median follow-up of almost 2 years (22 months; range, 6-58 months), limb salvage was achieved in 82%. Regional toxicity was limited and systemic toxicity minimal to moderate, easily managed, with no toxic deaths. CONCLUSIONS: In the setting of isolated limb perfusion, TNF is an active anticancer drug in patients. The ILP with TNF + melphalan can be performed safely in many centers and is an effective induction treatment with a high response rate that can achieve limb salvage in patients with locally advanced extremity soft tissue sarcoma.
445 citations
••
TL;DR: The approach expands the utility of CRISPR-Cas9 to elucidate the functions of the noncoding genome by identifying several functional enhancer elements and characterized the role of two of them in mediating p53 (TP53) and ERα (ESR1) gene regulation.
Abstract: Systematic identification of noncoding regulatory elements has, to date, mainly relied on large-scale reporter assays that do not reproduce endogenous conditions. We present two distinct CRISPR-Cas9 genetic screens to identify and characterize functional enhancers in their native context. Our strategy is to target Cas9 to transcription factor binding sites in enhancer regions. We identified several functional enhancer elements and characterized the role of two of them in mediating p53 (TP53) and ERα (ESR1) gene regulation. Moreover, we show that a genomic CRISPR-Cas9 tiling screen can precisely map functional domains within enhancer elements. Our approach expands the utility of CRISPR-Cas9 to elucidate the functions of the noncoding genome.
353 citations
Authors
Showing all 945 results
Name | H-index | Papers | Citations |
---|---|---|---|
Patrick W. Serruys | 186 | 2427 | 173210 |
Wim C. J. Hop | 110 | 642 | 46690 |
Jan H.M. Schellens | 98 | 921 | 44992 |
Pim J. de Feyter | 94 | 492 | 33728 |
Maarten L. Simoons | 90 | 415 | 54201 |
Wiro J. Niessen | 85 | 571 | 30461 |
Matthijs Oudkerk | 83 | 583 | 27786 |
Suresh Senan | 79 | 523 | 25897 |
Bruce H. R. Wolffenbuttel | 76 | 447 | 26974 |
Ron T. van Domburg | 75 | 517 | 24484 |
Alexander M.M. Eggermont | 73 | 410 | 20753 |
Bettina E. Hansen | 73 | 411 | 21430 |
Hubert G. M. Niesters | 70 | 324 | 16571 |
Jan Bakker | 69 | 461 | 18991 |
Jaap W. Deckers | 68 | 268 | 37766 |